Losartan

"Losartan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.

Descriptor ID	D019808
MeSH Number(s)	D02.455.426.559.389.185.475 D03.383.129.308.507 D03.383.129.617.467
Concept/Terms	Losartan Losartan 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol DuP-753 DuP-753 DuP 753 DuP753 MK-954 MK-954 MK 954 MK954 Cozaar Cozaar Losartan Potassium Losartan Potassium Potassium, Losartan Losartan Monopotassium Salt Monopotassium Salt, Losartan Salt, Losartan Monopotassium

Below are MeSH descriptors whose meaning is more general than "Losartan".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Hydrocarbons [D02.455]
Hydrocarbons, Cyclic [D02.455.426]
Hydrocarbons, Aromatic [D02.455.426.559]
Benzene Derivatives [D02.455.426.559.389]
Biphenyl Compounds [D02.455.426.559.389.185]
Losartan [D02.455.426.559.389.185.475]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Azoles [D03.383.129]
Imidazoles [D03.383.129.308]
Losartan [D03.383.129.308.507]
Tetrazoles [D03.383.129.617]
Losartan [D03.383.129.617.467]

Below are MeSH descriptors whose meaning is related to "Losartan".

Below are MeSH descriptors whose meaning is more specific than "Losartan".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Losartan" by people in this website by year, and whether "Losartan" was a major or minor topic of these publications.

Bar chart showing 33 publications over 21 distinct years, with a maximum of 3 publications in 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1993	0	2	2
1995	0	1	1
1996	0	2	2
1997	0	1	1
1998	0	1	1
1999	0	1	1
2000	0	1	1
2002	0	1	1
2003	0	1	1
2004	1	1	2
2006	2	0	2
2008	1	1	2
2010	0	2	2
2011	0	2	2
2012	1	0	1
2013	1	2	3
2014	1	1	2
2015	1	0	1
2016	0	1	1
2018	2	0	2
2020	1	1	2

Below are the most recent publications written about "Losartan" by people in Profiles.

Hamstra MS, Pemberton VL, Dagincourt N, Hollenbeck-Pringle D, Trachtenberg FL, Cnota JF, Atz AM, Cappella E, De Nobele S, Grima J, King M, Korsin R, Lambert LM, MacNeal MK, Markham LW, MacCarrick G, Sylvester DM, Walter P, Xu M, Lacro RV. Recruitment, retention, and adherence in a clinical trial: The Pediatric Heart Network's Marfan Trial experience. Clin Trials. 2020 12; 17(6):684-695.

View in: PubMed
Van Driest SL, Sleeper LA, Gelb BD, Morris SA, Dietz HC, Forbus GA, Goldmuntz E, Hoskoppal A, James J, Lee TM, Levine JC, Li JS, Loeys BL, Markham LW, Meester JAN, Mital S, Mosley JD, Olson AK, Renard M, Shaffer CM, Sharkey A, Young L, Lacro RV, Roden DM. Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. J Pediatr. 2020 07; 222:213-220.e5.

View in: PubMed
Handisides JC, Hollenbeck-Pringle D, Uzark K, Trachtenberg FL, Pemberton VL, Atz TW, Bradley TJ, Cappella E, De Nobele S, Groh GK, Hamstra MS, Korsin R, Levine JC, Lindauer B, Liou A, Neal MKM, Markham LW, Morrison T, Mussatto KA, Olson AK, Pierpont MEM, Pyeritz RE, Radojewski EA, Roman MJ, Xu M, Lacro RV. Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. J Pediatr. 2019 01; 204:250-255.e1.

View in: PubMed
Selamet Tierney ES, Levine JC, Sleeper LA, Roman MJ, Bradley TJ, Colan SD, Chen S, Campbell MJ, Cohen MS, De Backer J, Heydarian H, Hoskoppal A, Lai WW, Liou A, Marcus E, Nutting A, Olson AK, Parra DA, Pearson GD, Pierpont ME, Printz BF, Pyeritz RE, Ravekes W, Sharkey AM, Srivastava S, Young L, Lacro RV. Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome. Am J Cardiol. 2018 05 01; 121(9):1094-1101.

View in: PubMed
DeLeon-Pennell KY. May the fibrosis be with you: Is discoidin domain receptor 2 the receptor we have been looking for? J Mol Cell Cardiol. 2016 Feb; 91:201-3.

View in: PubMed
Kwon OS, Smuder AJ, Wiggs MP, Hall SE, Sollanek KJ, Morton AB, Talbert EE, Toklu HZ, Tumer N, Powers SK. AT1 receptor blocker losartan protects against mechanical ventilation-induced diaphragmatic dysfunction. J Appl Physiol (1985). 2015 Nov 15; 119(10):1033-41.

View in: PubMed
Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, Pearson GD, Selamet Tierney ES, Levine JC, Atz AM, Benson DW, Braverman AC, Chen S, De Backer J, Gelb BD, Grossfeld PD, Klein GL, Lai WW, Liou A, Loeys BL, Markham LW, Olson AK, Paridon SM, Pemberton VL, Pierpont ME, Pyeritz RE, Radojewski E, Roman MJ, Sharkey AM, Stylianou MP, Wechsler SB, Young LT, Mahony L. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014 Nov 27; 371(22):2061-71.

View in: PubMed
Toklu HZ, Kwon OS, Sakarya Y, Powers SK, Llinas K, Kirichenko N, Sollanek KJ, Wiggs MP, Smuder AJ, Talbert EE, Scarpace PJ, Tümer N. The effects of enalapril and losartan on mechanical ventilation-induced sympathoadrenal activation and oxidative stress in rats. J Surg Res. 2014 May 15; 188(2):510-6.

View in: PubMed
Gallo EM, Loch DC, Habashi JP, Calderon JF, Chen Y, Bedja D, van Erp C, Gerber EE, Parker SJ, Sauls K, Judge DP, Cooke SK, Lindsay ME, Rouf R, Myers L, ap Rhys CM, Kent KC, Norris RA, Huso DL, Dietz HC. Angiotensin II-dependent TGF-ß signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J Clin Invest. 2014 Jan; 124(1):448-60.

View in: PubMed
Wilson PC, Lee MH, Appleton KM, El-Shewy HM, Morinelli TA, Peterson YK, Luttrell LM, Jaffa AA. The arrestin-selective angiotensin AT1 receptor agonist [Sar1,Ile4,Ile8]-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers. J Biol Chem. 2013 Jun 28; 288(26):18872-84.

View in: PubMed

People

Explore

Similar Concepts

Top Journals